396 related articles for article (PubMed ID: 10729660)
21. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.
Liaw SJ; Wu HC; Hsueh PR
Clin Microbiol Infect; 2010 Jun; 16(6):696-703. PubMed ID: 19694765
[TBL] [Abstract][Full Text] [Related]
22. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
[TBL] [Abstract][Full Text] [Related]
23. Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS.
Rodero L; Córdoba S; Cahn P; Soria M; Lucarini M; Davel G; Kaufman S; Canteros C; Guelfand L
Med Mycol; 2000 Jun; 38(3):201-7. PubMed ID: 10892987
[TBL] [Abstract][Full Text] [Related]
24. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
25. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
[TBL] [Abstract][Full Text] [Related]
26. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.
Arechavala AI; Ochiuzzi ME; Borgnia MD; Santiso GM
Rev Iberoam Micol; 2009 Sep; 26(3):194-7. PubMed ID: 19635445
[TBL] [Abstract][Full Text] [Related]
27. Current scenario of cryptococcosis and antifungal susceptibility pattern in India: a cause for reappraisal.
Capoor MR; Mandal P; Deb M; Aggarwal P; Banerjee U
Mycoses; 2008 May; 51(3):258-65. PubMed ID: 18399907
[TBL] [Abstract][Full Text] [Related]
28. Turbidimetric and visual criteria for in vitro susceptibility testing of Cryptococcus neoformans clinical isolates.
Del Poeta M; Barchiesi F; Arzeni D; Marinucci G; Scalise G
Mycoses; 1994; 37(11-12):411-6. PubMed ID: 7659128
[TBL] [Abstract][Full Text] [Related]
29. Cryptococcus neoformans varieties as agents of cryptococcosis in Brazil.
Rozenbaum R; Gonçalves AJ; Wanke B; Caiuby MJ; Clemente H; Lazera Mdos S; Monteiro PC; Londero AT
Mycopathologia; 1992 Sep; 119(3):133-6. PubMed ID: 1435954
[TBL] [Abstract][Full Text] [Related]
30. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya.
Mdodo R; Moser SA; Jaoko W; Baddley J; Pappas P; Kempf MC; Aban I; Odera S; Jolly P
Mycoses; 2011 Sep; 54(5):e438-42. PubMed ID: 21535451
[TBL] [Abstract][Full Text] [Related]
31. Antifungal susceptibility of the clinical and environmental strains of Cryptococcus gattii sensu lato in Taiwan.
Lin KH; Lai YC; Lin YP; Ho MW; Chen YC; Chung WH
Mycoses; 2023 Jan; 66(1):13-24. PubMed ID: 35986599
[TBL] [Abstract][Full Text] [Related]
32. Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients.
Jessup CJ; Pfaller MA; Messer SA; Zhang J; Tumberland M; Mbidde EK; Ghannoum MA
J Clin Microbiol; 1998 Oct; 36(10):2874-6. PubMed ID: 9738036
[TBL] [Abstract][Full Text] [Related]
33. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
34. In vitro susceptibility of Cryptococcus neoformans serotypes to GM 237354 derivative of the sordarin class.
Torres-Rodríguez JM; Morera Y; Baró T; López O; Alía C; Jiménez T
Mycoses; 2002 Oct; 45(8):313-6. PubMed ID: 12572721
[TBL] [Abstract][Full Text] [Related]
35. In vitro susceptibility of Cryptococcus neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method.
López-Jodra O; Torres-Rodríguez JM; Méndez-Vásquez R; Ribas-Forcadell E; Morera-López Y; Baró-Tomás T; Alia-Aponte C
J Antimicrob Chemother; 2000 May; 45(5):645-9. PubMed ID: 10797087
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
[TBL] [Abstract][Full Text] [Related]
37. Clinical and microbiological characteristics of cryptococcosis in Singapore: predominance of Cryptococcus neoformans compared with Cryptococcus gattii.
Chan M; Lye D; Win MK; Chow A; Barkham T
Int J Infect Dis; 2014 Sep; 26():110-5. PubMed ID: 25018090
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
[TBL] [Abstract][Full Text] [Related]
39. Flucytosine and cryptococcosis: which in vitro test is the best predictor of outcome?
Viviani MA; Esposto MC; Cogliati M; Tortorano AM
J Chemother; 2003 Apr; 15(2):124-8. PubMed ID: 12797387
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
